Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
08
06
2020
revised:
04
10
2020
accepted:
28
12
2020
pubmed:
25
3
2021
medline:
5
10
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units. This may contribute to differences in survival. This cluster RCT evaluated the impact of decision support interventions (DESIs) for older women with breast cancer, to ascertain whether DESIs influenced quality of life, survival, decision quality, and treatment choice. A multicentre cluster RCT compared the use of two DESIs against usual care in treatment decision-making in older women (aged at least ≥70 years) with breast cancer. Each DESI comprised an online algorithm, booklet, and brief decision aid to inform choices between surgery plus adjuvant endocrine therapy versus primary endocrine therapy, and adjuvant chemotherapy versus no chemotherapy. The primary outcome was quality of life. Secondary outcomes included decision quality measures, survival, and treatment choice. A total of 46 breast units were randomized (21 intervention, 25 usual care), recruiting 1339 women (670 intervention, 669 usual care). There was no significant difference in global quality of life at 6 months after the baseline assessment on intention-to-treat analysis (difference -0.20, 95 per cent confidence interval (C.I.) -2.69 to 2.29; P = 0.900). In women offered a choice of primary endocrine therapy versus surgery plus endocrine therapy, knowledge about treatments was greater in the intervention arm (94 versus 74 per cent; P = 0.003). Treatment choice was altered, with a primary endocrine therapy rate among women with oestrogen receptor-positive disease of 21.0 per cent in the intervention versus 15.4 per cent in usual-care sites (difference 5.5 (95 per cent C.I. 1.1 to 10.0) per cent; P = 0.029). The chemotherapy rate was 10.3 per cent at intervention versus 14.8 per cent at usual-care sites (difference -4.5 (C.I. -8.0 to 0) per cent; P = 0.013). Survival was similar in both arms. The use of DESIs in older women increases knowledge of breast cancer treatment options, facilitates shared decision-making, and alters treatment selection. Trial registration numbers: EudraCT 2015-004220-61 (https://eudract.ema.europa.eu/), ISRCTN46099296 (http://www.controlled-trials.com).
Sections du résumé
BACKGROUND
Rates of surgery and adjuvant therapy for breast cancer vary widely between breast units. This may contribute to differences in survival. This cluster RCT evaluated the impact of decision support interventions (DESIs) for older women with breast cancer, to ascertain whether DESIs influenced quality of life, survival, decision quality, and treatment choice.
METHODS
A multicentre cluster RCT compared the use of two DESIs against usual care in treatment decision-making in older women (aged at least ≥70 years) with breast cancer. Each DESI comprised an online algorithm, booklet, and brief decision aid to inform choices between surgery plus adjuvant endocrine therapy versus primary endocrine therapy, and adjuvant chemotherapy versus no chemotherapy. The primary outcome was quality of life. Secondary outcomes included decision quality measures, survival, and treatment choice.
RESULTS
A total of 46 breast units were randomized (21 intervention, 25 usual care), recruiting 1339 women (670 intervention, 669 usual care). There was no significant difference in global quality of life at 6 months after the baseline assessment on intention-to-treat analysis (difference -0.20, 95 per cent confidence interval (C.I.) -2.69 to 2.29; P = 0.900). In women offered a choice of primary endocrine therapy versus surgery plus endocrine therapy, knowledge about treatments was greater in the intervention arm (94 versus 74 per cent; P = 0.003). Treatment choice was altered, with a primary endocrine therapy rate among women with oestrogen receptor-positive disease of 21.0 per cent in the intervention versus 15.4 per cent in usual-care sites (difference 5.5 (95 per cent C.I. 1.1 to 10.0) per cent; P = 0.029). The chemotherapy rate was 10.3 per cent at intervention versus 14.8 per cent at usual-care sites (difference -4.5 (C.I. -8.0 to 0) per cent; P = 0.013). Survival was similar in both arms.
CONCLUSION
The use of DESIs in older women increases knowledge of breast cancer treatment options, facilitates shared decision-making, and alters treatment selection. Trial registration numbers: EudraCT 2015-004220-61 (https://eudract.ema.europa.eu/), ISRCTN46099296 (http://www.controlled-trials.com).
Identifiants
pubmed: 33760077
pii: 6182547
doi: 10.1093/bjs/znab005
pmc: PMC10364907
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-510Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
BMC Surg. 2013;13 Suppl 2:S25
pubmed: 24267004
J Clin Oncol. 2011 Jan 1;29(1):89-96
pubmed: 21098316
Psychooncology. 2015 Dec;24(12):1761-6
pubmed: 26043439
J Clin Oncol. 1996 Oct;14(10):2756-68
pubmed: 8874337
Clin Oncol (R Coll Radiol). 2019 Jul;31(7):444-452
pubmed: 31122807
Psychooncology. 2015 Aug;24(8):878-84
pubmed: 25534045
Br J Surg. 2020 Oct;107(11):1468-1479
pubmed: 32488911
Cancer. 2019 Jun 1;125(11):1807-1814
pubmed: 30707774
Med Decis Making. 2001 Jan-Feb;21(1):1-6
pubmed: 11206942
Ann Surg. 2011 Sep;254(3):438-42; discussion 442-3
pubmed: 21775882
Patient Prefer Adherence. 2019 Jan 14;13:131-143
pubmed: 30679905
Nutrition. 1996 Jan;12(1 Suppl):S15-9
pubmed: 8850213
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Br J Surg. 2020 Aug;107(9):1145-1153
pubmed: 32259294
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Breast. 2016 Apr;26:31-45
pubmed: 27017240
Br J Cancer. 2018 Jul;119(1):121-129
pubmed: 29875471
J Clin Oncol. 2018 Mar 1;36(7):659-666
pubmed: 29364772
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):882-890
pubmed: 29485067
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
J Med Internet Res. 2014 Jan 03;16(1):e2
pubmed: 24389354
CMAJ. 2012 Mar 20;184(5):533-40
pubmed: 22392947
Psychooncology. 2008 Apr;17(4):410-6
pubmed: 17847124
Br J Cancer. 2016 Feb 16;114(4):395-400
pubmed: 26783995
Br J Surg. 2015 Aug;102(9):1056-63
pubmed: 26095684
J Clin Oncol. 2005 Apr 20;23(12):2716-25
pubmed: 15837986
Psychooncology. 2017 Dec;26(12):2094-2100
pubmed: 28332254
J Am Geriatr Soc. 2019 May;67(5):920-927
pubmed: 30146695
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
JAMA Surg. 2018 Dec 1;153(12):1090-1096
pubmed: 30167636
J Clin Oncol. 2007 Aug 20;25(24):3699-704
pubmed: 17704418
J Geriatr Oncol. 2018 Mar;9(2):152-162
pubmed: 29167064
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Br J Cancer. 2004 Apr 19;90(8):1486-91
pubmed: 15083173
BMJ Open. 2017 Jul 31;7(7):e015133
pubmed: 28760787
BMC Med Inform Decis Mak. 2015 Jun 10;15:45
pubmed: 26058557
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet. 1999 Jul 10;354(9173):130-1
pubmed: 10408495
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Lancet Oncol. 2012 Apr;13(4):e148-60
pubmed: 22469125
Lancet Oncol. 2014 Jun;15(7):722-9
pubmed: 24836274
Br J Clin Psychol. 1992 Sep;31(3):301-6
pubmed: 1393159
Eur J Cancer. 2010 Aug;46(12):2242-52
pubmed: 20580993
Eur J Surg Oncol. 2014 Jun;40(6):676-84
pubmed: 24703110
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
Med Decis Making. 2003 Jul-Aug;23(4):281-92
pubmed: 12926578
Psychooncology. 2019 Jul;28(7):1367-1380
pubmed: 30838697
JAMA. 2004 Jul 28;292(4):435-41
pubmed: 15280341
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
Cochrane Database Syst Rev. 2014 May 19;5:CD004272
pubmed: 35658165
Eur J Surg Oncol. 2015 Sep;41(9):1234-42
pubmed: 26108734
Nutr Cancer. 2005;53(1):51-6
pubmed: 16351506
J Natl Cancer Inst. 2020 Jun 1;112(6):574-581
pubmed: 31612208
Plast Reconstr Surg. 2008 Sep;122(3):717-724
pubmed: 18766034
Br J Surg. 2018 Oct;105(11):1454-1463
pubmed: 29790154
Eur J Surg Oncol. 2017 Jul;43(7):1282-1287
pubmed: 28237423
Br J Surg. 2007 Oct;94(10):1209-15
pubmed: 17590857
J Natl Cancer Inst. 2003 Apr 16;95(8):581-7
pubmed: 12697850
Stat Med. 2005 Apr 30;24(8):1185-202
pubmed: 15568194